B-cell Leukemia
15
4
4
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (15)
CAR-T Immunotherapy Targeting CD19- ALL
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies
CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients
CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy
CAR T Cells for Refractory B Cell Malignancy
Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma